CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting
Clinical Pharmacology & Therapeutics · 2026-08 · 120 (2) · 412-419
DOI: 10.1002/cpt.70285 ↗At a glance
Journal article in Clinical Pharmacology & Therapeutics, published online on 2026-04-14. Written by Yoomi Park and 2 co-authors. Institution: Department of Physiology and Pharmacology and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden. Major MEDLINE topics: Cytochrome P-450 CYP2C19, Citalopram, Selective Serotonin Reuptake Inhibitors. Cited 1 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from the UK Biobank. Importantly, CYP2C19 ultrarapid metabolizers (UMs) were more likely to experience therapeutic failure (OR 2.03, P = 0.002) and both CYP2C19 poor metabolizers (PMs) and UMs exhibited an increased likelihood of treatment resistance (PMs, OR 1.85, P = 0.06; UMs, OR 1.74, P = 0.05). Furthermore, inferred CYP2C19 metabolizer status showed significant monotonic trends with citalopram maintenance dose (from 19.7 mg/d in PMs to 24.4 mg/d in UMs; Jonckheere–Terpstra P = 0.017) and time to dose escalation (2.5 years in PMs to 1.7 years in UMs; P = 0.006). Besides CYP2C19 , rare variant analyses identified BMP2K as a novel candidate locus for SSRI response. BMP2K variants were significantly associated with therapeutic failure in citalopram patients ( P = 5.49 × 10 −6 ) and this association was replicated in 220 escitalopram users ( P = 0.042). Furthermore, higher BMP2K variant burden significantly correlated with lower maintenance dose. These findings provide the first report of a U‐shaped association between CYP2C19 metabolizer status and citalopram therapeutic outcomes and pinpoint BMP2K as a novel candidate gene with potential contribution to interindividual differences in citalopram response. Collectively, these results demonstrate that CYP2C19 genotype is significantly associated with citalopram outcomes in a real‐world setting in which patient treatment was not guided by pharmacogenetics, thus avoiding open‐label awareness, eliminating expectation bias of genetic testing and highlighting the value of large‐scale biobank data for advancing precision psychiatry.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Physiology and Pharmacology and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.
- Medical Research Center, Seoul National University College of Medicine, Seoul, South Korea.
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
- University of Tübingen, Tübingen, Germany.
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.
ORCID profiles: Yoomi Park, Yitian Zhou, Volker M Lauschke
Cite
APA
Park, Y., Zhou, Y., & Lauschke, V. M. (2026). CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting. Clinical Pharmacology & Therapeutics, 120(2), 412-419. https://doi.org/10.1002/cpt.70285
Vancouver
Park Y, Zhou Y, Lauschke VM. CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting. Clinical Pharmacology & Therapeutics. 2026;120(2):412-419. doi:10.1002/cpt.70285
BibTeX
@article{Park2026,
author = {Park, Yoomi and Zhou, Yitian and Lauschke, Volker M},
title = {CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {120},
number = {2},
pages = {412--419},
doi = {10.1002/cpt.70285}
}
EUVIMED